title: [18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.
abstract: OBJECTIVE
  The objective of the present study is to determine whether uptake of [(18)F]fluoromethylcholine ([(18)F]FCH) in comparison with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) accurately reflects chemotherapy efficacy at the tumor cell level in prostate cancer (PC).
  
  
  METHODS
  The effects of docetaxel and cabazitaxel on viable tumor cell number were explored in four PC cell lines. Cellular uptake of [(18)F]FDG and [(18)F]FCH was compared with the effects measured using sulforhodamine B (SRB) assay, cell counting and colony formation assay (CFA), as proximators of viable tumor cell number. Agreement between uptake and cell numbers was assessed by Bland-Altman plots.
  
  
  RESULTS
  [(18)F]FCH uptake in all PC cell lines significantly correlated to the cell numbers surviving the respective drug concentrations. Bland-Altman analysis showed that [(18)F]FDG uptake resulted in signal overestimation and higher variability after chemotherapy.
  
  
  CONCLUSIONS
  [(18)F]FCH uptake correlates well with viable tumor cell numbers remaining after docetaxel and cabazitaxel exposure. Radiolabeled choline is a potential response monitoring biomarker after chemotherapy for PC.
authors.affiliation: Department of Radiology and Nuclear Medicine, VU University Medical Center, PO Box 7057, 1007, MB, Amsterdam, The Netherlands.
authors.forename: Daniela E
authors.initials: DE
authors.lastname: Oprea-Lager
authors.forename: Mitchell P
authors.initials: MP
authors.lastname: van Kanten
authors.forename: Reindert J A
authors.initials: RJ
authors.lastname: van Moorselaar
authors.forename: Alfons J M
authors.initials: AJ
authors.lastname: van den Eertwegh
authors.forename: Peter M
authors.initials: PM
authors.lastname: van de Ven
authors.forename: Irene V
authors.initials: IV
authors.lastname: Bijnsdorp
authors.forename: Otto S
authors.initials: OS
authors.lastname: Hoekstra
authors.forename: Albert A
authors.initials: AA
authors.lastname: Geldof
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor / Q000187:drug effects; D002794:Choline / Q000031:analogs & derivatives* / Q000737:chemistry; D000077143:Docetaxel; D004354:Drug Screening Assays, Antitumor; D005462:Fluorine Radioisotopes / Q000737:chemistry*; D019788:Fluorodeoxyglucose F18 / Q000737:chemistry; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000737:chemistry; D012235:Rhodamines / Q000737:chemistry; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D012235:Rhodamines; D043823:Taxoids; C516370:fluoromethylcholine; D019788:Fluorodeoxyglucose F18; D000077143:Docetaxel; C022027:lissamine rhodamine B; C552428:cabazitaxel; D002794:Choline